抗血管生成基因治疗人脑胶质瘤的实验研究
|
摘要
血管生成(angiogenesis)是指从已存在的血管床中产生出新生血管系统的复杂过程。这一过程受控于多种血管生成因子和抑制因子。正常血管形成被严格限定于某些特定短暂的生理过程，如胚胎发生和伤口愈合等；而持续的血管生成则是某些病理改变的特征，如肿瘤血管生成。肿瘤细胞是肿瘤血管生成的组织者，它能过量表达几种促血管生长因子，如血管内皮细胞生长因子(vascular endothelial growth factor, VEGF)、成纤维细胞生长因子(fibroblast growth factor, FGF)和血管产生素(angiopoietin)等；分泌多种酶，如尿激酶(urokinase-type plasminogen activator, u-PA)和基质金属蛋白酶(matrix metalloproteinase, MMP)；从细胞外基质中调动所需要的蛋白和酶，如整合素α_vβ_3(integrin α_vβ_3)和整合素α_vβ_5(integrin α_vβ_5)；征募宿主细胞，如巨噬细胞、淋巴细胞、纤维细胞，使它们分泌促血管生长因子。各类促血管生长因子过量表达和血管生成抑制因子下调是导致肿瘤血管增生，引起肿瘤生长和转移的基础。
研究表明，实体瘤生长和转移依赖于血管生成。肿瘤形成早期(血管前期)，没有血管生长，此期肿瘤不超过0.4mm~3，呈缓慢的线性生长。当肿瘤大小超过0.4mm~3时(血管期)，肿瘤开始形成自身的血管系统，并呈快速的近指数生长，其特征是肿瘤生长加速，并依赖于肿瘤血管床延伸出现远处转移。因此，在“血
Angiogenesis, the formation of new capillary blood vessels from pre-existing ones, is a complicated process, which is controlled by many angiogenesis stimulating factors and inhibitory factors. Normal angiogenesis is strictly limited to some special transient physiological processes, such as embryogenesis, wound repair, and etc. But continuous angiogenesis is the characteristic of some pathlogical changes, such as tumor angiogenesis.The tumor cell is the organizer for its angiogenesis.It can overexpress several angiogenesis stimulating factors(such as VEGF , FGF , angiopoietin and etc), secrete many enzymes(such as uPA and MMP), mobilize the needed proteins and enzymes from the cell matrix(such as integrin α_v β_3 and α_v β_5), recruit the host cells to secrete promoting angiogenesis factors(macrophage, lymphocyte and fibroblast). Both upregulation of angiogenic stimulators and downregulation of angiogenesis inhibitors result in tumor blood vessel proliferation, which is the bases of the tumor growth and metastasis.
Direct experimental evidences show that solid tumor growth and metastasis require new blood vessels. An avascular tumor (vascular prophase) rarely grows to a size larger than 0.4 mm~3 and grows at a slow linear growth speed. Once a tumor
研究表明，实体瘤生长和转移依赖于血管生成。肿瘤形成早期(血管前期)，没有血管生长，此期肿瘤不超过0.4mm~3，呈缓慢的线性生长。当肿瘤大小超过0.4mm~3时(血管期)，肿瘤开始形成自身的血管系统，并呈快速的近指数生长，其特征是肿瘤生长加速，并依赖于肿瘤血管床延伸出现远处转移。因此，在“血
Angiogenesis, the formation of new capillary blood vessels from pre-existing ones, is a complicated process, which is controlled by many angiogenesis stimulating factors and inhibitory factors. Normal angiogenesis is strictly limited to some special transient physiological processes, such as embryogenesis, wound repair, and etc. But continuous angiogenesis is the characteristic of some pathlogical changes, such as tumor angiogenesis.The tumor cell is the organizer for its angiogenesis.It can overexpress several angiogenesis stimulating factors(such as VEGF , FGF , angiopoietin and etc), secrete many enzymes(such as uPA and MMP), mobilize the needed proteins and enzymes from the cell matrix(such as integrin α_v β_3 and α_v β_5), recruit the host cells to secrete promoting angiogenesis factors(macrophage, lymphocyte and fibroblast). Both upregulation of angiogenic stimulators and downregulation of angiogenesis inhibitors result in tumor blood vessel proliferation, which is the bases of the tumor growth and metastasis.
Direct experimental evidences show that solid tumor growth and metastasis require new blood vessels. An avascular tumor (vascular prophase) rarely grows to a size larger than 0.4 mm~3 and grows at a slow linear growth speed. Once a tumor
引文
1. Risau W. Mechanisms of angiogenesis. Nature 1997; 386:671-4.
2. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267:10931-4.
3. Shalaby F.Failure of blood-island formation and vasculogenesis in fit-1-deficient mice.Nature.1995; 376:62-66
4. Breier G, Risau W. The role of VEGF in blood vessel formation. Trends Cell Biol.l996;6:454-456
5. Sato TN. Distinct roles of the receptor tyrosine kinases tie-1 and tie-2 in blood vessel formation.Nature.1995; 376:70-74
6. Henkemeyer M.Vascular system defects and neuronal apoptosis in mice lacking Ras GTPase activating protein.Nature.l984;307:648-649
7. Federico B, Alberto M, Graziella P, et al. Molecular mechanisms of blood vessel formation.Trends in Biochenmical Sciences. 1997;22(7):251 -256
8. Werner Risau. Mechanism of angiogenesis. Nature. 1997, 386:671-674
9. Dameron KM, Volpert OV, Tainsky MA,et al. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb Symp Quant Biol 1994; 59:483-9.
10. Rastinejad F, Polverini PJ, Bouck NP. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989; 56:345-55.
11. Plate KH, Breier G, Millauer B, et al. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat gliorna model of tumor angiogenesis. Cancer Res 1993; 53:58227.
12. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992; 359: 843-5
13. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145:574-84
14. Minchenko A, Bauer T, Salceda S, et al. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest. 1994; 71:374-9
15. Ensoli B, Gendelman R, Markham P, et al. Synergy between basic fibroblast growth factor and HIVA Tat protein in induction of Kaposi's sarcoma. Nature 1994; 371:674-80.
16. Nguyen JT, Wu P, Clouse MF, et al. Adcno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res.1998; 58:5673-7
17. Hannan RL, Kourembanas S, Flanders KC, et al. Endothelial cells synthesize basic fibroblast growth factor and transforming growth factor beta. Growth Factors. 1988; 1: 7-17
18. Mignatti P, Rifkin DB. Release of basic fibroblast growth factor, an angiogenic factor devoid of secretory signal sequence: a trivial phenomenon or a novel secretion mechanism? J Cell Biochem. 1991; 47:201-7
19. Klagsbrun M, D'Amore PA. Regulators of angiogenesis. Annu Rev Physiol. 1991; 53:217-39
20. Hori A, Sasada R, Matsutani E, et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res. 1991; 51:6180-4
21. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem. 1996; 271:603-6
22. Stokes CL, Rupnick MA, Williams SK, et al. Chemotaxis of human microvessel endothelial cells in response to acidic fibroblast growth factor. Lab Invest. 1990; 63:657-68
23. Guo D, Jia Q, Song HY, Warren Rs et al. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem. 1995; 270:6729-33
24. Relf M, LeJeune S, Scott PA et al. Expression of the angiogenic factors: vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997; 57:963-9
25. Gnarra JR, Duan DR, Weng Y et al. Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta. 1996; 1242:201-10
26. Yang EY, Moses HL. Transforming growth factor beta 1 -induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol. 1990; 111:731-41
27. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995; 146:1029-39
28. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Fit4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. Embo J. 1996; 15:290-98
29. Maglione D, Guerriero V, Viglietto G, et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A. 1991; 88:9267-71
30．寿成超．血管内皮细胞的增殖调节与抗血管肿瘤生物治疗．中国肿瘤生物治疗杂志．1999，6(3)：175～176
31. Bagavandoss P, Wilks JW. Specific inhibition of endothelial cell proliferation by thrombospondin. Biochern Biophys Res Commun. 1990; 170:867-7231
32. Rastinejad F, Polverini PJ, Bouck NP. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell; 1989; 56:345-55
33. Tolsma SS, Volpert OV, Good DJ et al. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol. 1993; 122:497-511
34．袁玫．靶向血管治疗肿瘤的研究进展．中国肿瘤生物治疗杂志．1999，6(3)：177～178
35. Sgadari C, Angiolillo AL, Cherney BW et al. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci U S A. 1996; 93:13791-6
36. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol. 1997; 61:246-57
37. Harmeken A, Ying W, Ling N, et al. Identification of soluble forms of the fibroblast growth factor receptor in blood. Proc Natl Acad Sci U S A.1994; 91:9170-4
38. Goldman CK, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A 1998; 95:8795-800
39. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994; 79:315-28
40. Dong Z, Yoneda J, Kumar R, et al. Angiostatin-mediated suppression of cancer metastases by primary, neoplasms engineered to produce granulocyte/macrophage colony stimulating factor. J Exp Med.1998; 188:755-63
41. Gately S, Twardowski P, Stack MS, et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci U S A. 1997; 94:10868-72
42. Cao Y, Ji RW, Davidson D, et al. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem. 1996; 271:29461-7
43. Cao Y, Chen A, An SSA, et al. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem. 1997; 272:22924-8
44. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma Cell 1994,79(2): 185-8
45. O'Reilly MS, Holmgren L, Chen C, et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996,2(6): 689-92
46. Dong Z, Kumar R, Yang X, et al. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997,88(6): 801-10
47. Gately S, Twardowski P, Stack MS, et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 1997,94(20): 10868-72
48. Sim BK, O'Reilly MS, Liang H, et al. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 1997,57(7): 1329-34
49. Marcia Barinaga. A Surprising Partner for Angiostatin. Cancer E A Surprising Partner for Angiostatin. Cancer Res.1999; 283(5409): 1831～3
50. O'Reilly MS, Holingren L, Chen C, Folkinan J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 1996; 2:689-92
51. Kim KJ, Li B, Winer J et al. inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362:841-4
52．吴景文，章翔．血管抑素与肿瘤的抗血管生成治疗．国外医学肿瘤学分册．1998；25(6)：16～17
53. Cao Y, O'Reilly MS, Marshall B, et al. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest. 1998, 101(5):1055-63
54. O'Reilly MS. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. EXS 1997;79:273-94
55. Oh SP, Kamagata Y, Muragaki Y et al. Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa, repeats identify a distinct family of collagenous proteins. Proc Nati Acad Sci U S A. 1994; 91:4229-33
56. Rehn M, Pihlajaniemi T. Identification of three N-terminal ends of type ⅩⅧ collagen chains and tissue specific differences in the expression of the corresponding transcripts. The longest form contains a novel motif homologous to rat and Drosophila frizzled proteins. J Biol Chem. 1995; 270:4705- 11
57. Muragaki Y, Timmons S, Griffith CM, et al. Mouse Coll. 8al is expressed in a tissuespecific manner as three alternative variants and is localized in basement membrane zones. Proc Natl Acad Sci U S A. 1995; 92:8763-7
58. Chen QR, Kumar D, Stass SA, et al. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 1999;59(14):3308-12
59. Cirri L, Donnini S, Morbidelli L, et al. Endostatin: a promising drug for antiangiogenic therapy. Int J Biol Markers 1999 Oct-Dec;14(4):263-7
60. Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997 ,390(6658):404-7
61. Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science. 1980; 208:516-8
62. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 1987; 47:5155-61
63. Voest EE, Kenyon BM, O'Reilly MS et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995; 87:581-6
64. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by interferon inducible protein. Blood. 1996; 87:3877-82
65. Yao L, Sgadari C, Furuke K et al. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood. 1999; 93:1612-21
66. Chen WT, Proteases associated with invadopodia with invadopodia, and their role in degradation of extracellular matrix. Enzyme Protein 1996; 49: 59-71
67. Johnson MD, Kim HR, Chesler L, Tsao-Wu G, Bouck N, Polverini PJ. Inhibition of angiogenesis by tissue inhibititor of metalloproteinase. J Cell Physiol 1994; 160: 194-202
68. Consalvo M, Mullen CA, Modesti A, et al. 5-Fluorocytosine-indueed eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 1995:154: 5302-12
69. Gastl G, Hermann T, Steurer M, et al. Angiogenesis as a target for tumor treatment. Oncology 1997; 54: 177-84
70. Wojtowicz-Praga S, Low J, Marshall J, et al. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in the patients with advanced cancer. Invest New Drugs. 1996; 14: 193-202
71. Folkman J, Iigber DE. Angiostatic steroids. Method of discovery and mechanism of action. Ann Surg 1987; 206: 374-83
72. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-63
73. Shokravi MT, Marcus DM, Alroy J, et al. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci. 1995;36:83-7
74. Ingber D, Fujita A, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature. 1990;348:555-7
75. Olson KA, Fett JW, French TC, et al. Angiogenin antagonists prevent tumor growth in vivo. Proc Natl Acad Sci USA. 1995;92: 442-6
76. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841-4.
77. Brook PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antigonists promote tumor regression by inducing apoptosis of angiogenic blood vessels.Cell.1994; 79:1157-64
78. Yeh CH, Peng HC, Huang TF. Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis. Blood, 1998; 92:3268-76
79. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:11826.
80. Panl MR. Starve the tumor, save the patient. The Lancet.1997, 349(11): 108-113
81. Folkman J. What is the evidence that tumors are angiogenesis dependent ? J Natl Cancer Inst. 1990,82(1):406
82. Folkman J, Watson K, Ingber D, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339:58-6 1
83. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324:1-8
84. Bouck N. Tumor angiogenesis: the role of oncogenes and tumor suppressor genes. Cancer cells. 1990; 2: 179-85
85. Dameron KM, Volpert OV, Tainsky MA, et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 1994; 265: 1582-4.
86. Folkman J, Waston K, Ingber D, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989; 339:58-61
87. Nanus DM, Schmitz-Drager BJ, Motzer RJ, et al. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst. 1993; 85:1597-9
88. Toim M, Hoshina S, Takayanagi A, et al. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary beast cancer. Jpn J Cancer Res. 1994; 85:1045-9
89. Takahashi Y, Kitadai Y, Bucana CD, et al. Expression of vascular endothlial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer. Cancer Res.1995; 55:3964-8
90. Yeicher BA, Holden SA, Ara G, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents, Int J Cancer. 1994; 57:920-5
91．董志伟．肿瘤控制与生物技术．中国肿瘤生物治疗杂志．1999，6 (3)：165
92. Burke F. Cytokines (IFNs, TNF-alpha, IL-2 and IL-12) and animal models of cancer. Cytokines Cell Mol Ther. 1999,5(1): 51-61
93. Nanni P, Forni G, Lollini PL. Cytokine gene therapy: hopes and pitfalls.Ann Oncol. 1999; 10(3): 261-6
94. Ockert D, Schmitz M, Hampl M, et al. Advances in cancer immunotherapy. Immunol Today. 1999; 20(2): 63-5
95. Prince HM. Gene transfer: a review of methods and applications. Pathology. 1998; 30(4): 335-47
96. Mueller H.Tumor necrosis factor as an antineoplastic agent: pitfalls and promises. Cell Mol Life Sci. 1998; 54(12): 1291-8
97. Kircheis R, Kupcu Z, Wallner G, et at. Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2+IFN-gamma. Cytokines Cell Mol Ther. 1998; 4(2): 95-103
98. Hwu P, Rosenberg SA.The genetic modification of T cells tbr cancer therapy: an overview of laboratory and clinical trials. Cancer Detect Prev. 1994; 18(1): 43-50
99. Pardoll DM. New strategies for enhancing the immunogenicity of tumors.Curr Opin Immunol. 1993; 5(5): 719-25
100. Kouraklis G. Progress in cancer gene therapy. Acta Oncol. 1999; 38(6): 675-83
101. Kuriyama S, Kikukawa M, Masui K, et al. Cancer gene therapy with HSV-tk/GCV system depends on Tcell-mediated immune responses and causes apoptotic death of tumor cells in vivo. Int J Cancer. 1999; 83(3): 374-80
102. Myers IN. The use of biological therapy in cancer of the head and neck. Curr Probl Cancer. 1999; 23(3): 106-34
103. Fueyo J, Gomez Manzano C, Yung WK, et al. Targeting in gene therapy for gliomas.Arch Neurol. 1999; 56(4): 445-8
104. Rainov NG, Ikeda K, Qureshi NH, et al. lntraarterial delivery, of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms. Hum Gene Ther. 1999; 10(2): 311-8
105. Sasaki M, Plate KH.Gene therapy of malignant glioma: recent advances in experimental and clinical studies. Ann Oncol. 1998; 9(11): 1155-66
106. Rosenberg SA. Immunotherapy and gene therapy of cancer. Cancer Res. 1991; 51 (18 Suppl): 5074s-5079s
107. Herrmann F. Cancer gene therapy: principles, problems, and perspectives. J Mol Med. 1995; 73(4): 157-63
108. Chen J, Gamou S, Takayanagi A, et al. Receptor-mediated gene delivery, using the Fab fragments of antiepidermal growth factor receptor antibodies: improved immunogene approach. Cancer Gene Ther. 1998; 5(6): 357-64
109. Fahraeus R, Fischer P, Krausz E, et al. New approaches to cancer therapies. J Pathol. 1999; 187(1): 138-46
110. Visse E, Siesjo P, Widegren B, et al. Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-gamma, interleukin-7, or B7-1-transfected tumor cells. Cancer Gene Yher. 1999; 6(1): 37-44
111. Horton HM, Anderson D, Hernandez P, et al. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc-Natl-Acad-Sci-U-S-A. 1999; 96(4): 1553-8
112. Wang JM, Deng X, Gong W, et al. Chemokines and their role in tumor growth and metastasis. J-Immunol-Methods. 1998; 220(1-2): 1-17
113. D'Angelica M, Fong Y. Cytokine gene therapy for human tumors.Surg Oncol Clin N Am. 1998; 7(3): 537-63
114. Chung RY, Chiocca EA. Gene therapy for tumors of the central nervous system.Surg Oncol Clin N Am. 1998; 7(3): 589-602
115. Mastrangelo MJ, Sato A, Lattime EC,et al. Cellular vaccine therapies for cancer. Cancer Treat Res. 1998; 94: 35-50
116. Weber CE. Cytokine-modified tumor vaccines: an antitumor strategy revisited in the age of molecular medicine. Cancer Nurs. 1998; 21(3): 167-77
117. Farzaneh F, Trefzer U, Sterry W, et al. Gene therapy of cancer. Immunol Today. 1998; 19(7): 294-6
118．崔正言．肿瘤疫苗的发展现状及其在肿瘤治疗中地位与前景．中国肿瘤生物治疗杂志．1999，6(3)：169
119. Kwak LW. Tumor vaccination strategies combined with autologous peripheral stem cell transplantation. Ann Oncol. 1998; 9 Suppl 1:S41-6
120. Gilboa E. Immunotherapy of cancer with genetically modified tumor vaccines. Semin Oncol. 1996; 23(1): 101-7
121. Hargest R, Williamson R. Expression of the APC gene after transfection into a colonic cancer cell line.Gut. 1995; 37(6): 826-9
122．钱振超．胂瘤疫苗的研究、直用与开发—21世纪的展望．中国肿痛生物治疗杂志．1999，6(3)：167—168
123．魏于全．肿瘤疫苗研究进展-利用异种细胞及异种基因进行肿瘤免疫治疗及基因治疗．中国肿瘤生物治疗杂志．1999，6(3)：176
124. Spear MA, Herrlinger U, Rainov N, et al. Targeting gene therapy vectors to CNS malignancies. J Neurovirol. 1998; 4(2): 133-47
125. Primus FJ, Finch MD, Wetzel SA, et al. Monoclonal antibody gene transfer: implications for tumor-specific cell-mediated cytotoxicity. Ann N Y Acad Sci. 1994; 716: 154o65; discussion 165-6
126. Mary, MN, Venot C, Caron de Fromentel C, et al. A tumor specific single chain antibody dependent on gene expression system. Oncogene. 1999; 18(2): 559-64
127．储大同．单克隆抗体的临床肿瘤应用进展．中国肿瘤生物治疗杂志．1999，6(3)：172
128. Spear MA. Gene therapy of gliomas: receptor and transcriptional targeting. Anticancer Res. 1998; 18(5A): 3223-31
129. Cirielli C, Capogrossi MC, Passaniti A. Anti-tumor gene therapy.J Neurooncol. 1997; 31 (1-2): 217-23
130. Hung MC, Matin A, Zhang Y, et al. HER-2/neu-targeting gene therapy-a review. Gene. 1995; 159(1): 65-71
131. Fathallah Shaykh H. New molecular strategies to cure brain tumors.Arch Neurol. 1999; 56(4): 449-53
132. Weyerbrock A, Oldfield EH. Gene transfer technologies for malignant gliomas. Curr Opin Oncol. 1999; 11(3): 168-73
133. Bellone M, Iezzi G, Imro MA, et al. Cancer immunotherapy: synthetic and natural peptides in the balance. Immunol Today. 1999, 20(10): 457-62
134. Braun SE, Chen K, Blazar BR, et al. Flt3 ligand antitumor activity in a murine breast cancer model: a comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action. Hum Gene Ther. 1999, 10(13): 2141-51
135. Avgeropoulos NG, Batchelor TT. New treatment strategies for malignant gliomas. Oncologist. 1999; 4(3): 209-24
136. Unger C. Current concepts of treatment in medical oncology: new anticancer drugs. J Cancer Res Clin Oncol. 1996; 122(4): 189-98
137. Mayer LD. Future developments in the selectivity of anticancer agents: drug delivery and molecular target strategies.Cancer Metastasis Rev. 1998; 17(2): 211-8
138. Ledley FD, Nonviral gene therapy: the promise of genes as pharmaceutical products. Hum Gene Ther. 1995; 6(9): 1129-44
139．丁锡申．基因重组药物的研究进展．中国肿瘤生物治疗杂志．1999．6(3)：173
140. Ronchetti A, Rovere P, Iezzi-G, et al. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J Immunol. 1999; 163(1): 130-6
141. McDonnell TJ, Meyn RE, Robertson LE. Implications of apoptotic cell death regulation in cancer therapy. Semin Cancer Biol. 1995; 6(1): 53-60
142．马大龙．细胞凋亡与肿瘤生物治疗．中国肿瘤生物治疗杂志．1999，6(3)：168
143. Cristiano RJ. Viral and non-viral vectors for cancer gene therapy. Anticancer Res. 1998; 18(5A): 3241-5
144. Cao Y.Therapeutic potentials of angiostatin in the treatment of cancer. Haematologica. 1999; 84(7): 643-50
145. Chen QR, Kumar D, Stass SA, et al. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res. 1999, 59(14): 3308-12
146. Malonne H, Langer I, Kiss R, et al. Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors. Clin-Exp-Metastasis. 1999; 17(1): 1-14
147. Blezinger P, Wang J, Gondo M, et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol. 1999; 17(4): 343-8
148. Liu Y, Thor A, Shtivelman E, et al. Systemic gene delivery expands the repertoire of effective antiangiogenic agents.J Biol Chem. 1999; 274(19): 13338-44
149. Lin P, Buxton JA, Acheson A, et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA. 1998; 95(15): 8829-34
150. Goldman CK, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc-Natl-Acad-Sci-U-S-A. 1998; 95(15): 8795-800
151. Paillard F. Suppression of angiogenesis: a means to fight cancer. Hum Gene Ther. 1998; 9(6): 768-70
152. Saleh M, Stacker SA, Wilks AF. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. 1996; 56(2): 393-401
153．寿超成．血管内皮细胞的增殖调节与抗血管肿瘤生物治疗．中国肿瘤生物治疗杂志．1999，6(3)：175-176
154．袁玫．靶向血管治疗肿瘤的研究进展．中国肿瘤生物治疗杂志．1999，6(3)：177
155. Ohnishi T, Sher PB, Posner HB et al. Capillary permeability factor secreted by malignant brain tumor: role in peritumoral grain edema and possible mechanism for antiedema effect of glucorticoids. J Neurosurgery,1990; 72:245-251
156. Folkman J, Shing Y. Angiogenesis. J Biol Chem, 1992; 267:10931-10934
157. KJ Kim, B Li, J Winer, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppress tumor growth in vivo. Nature, 1993;362:841-844
158. Saleh M, Stacker SA, Wilks A. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res,1996;56:393-401
159. Im SA, Gomez-Manzano C, Fueyo J, et al. Antiangiogenesis treatment for gliomas: transfer of antisensevascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res. 1999; 15; 59(4):895-900.
160. Weindel K, Moringlane JR, Marine D. Detection and quantification of vascular endothelial growth factor in brain tumor tissue and cyst fluid: the key to angiogenesis. Neurosurgery, 1994;35:439-449
161. Takano S. Suramin inhibits glioma cell proliferation in vitro and in the brain. J Neuro Oncol, 1994; 21:189-201
162. Fan TP. Angiosuppressive therapy for cancer. TIPS, 1994;1533-1535
163. Taki T, Ohnishi T, Arita N, et al. Anti-proliferative effects of TNP-470 on human malignant glioma in vivo: potent inhibition of tumor angiogenesis. J Neurooncol. 1994, 19(3): 251-258
164. Bernsen HJ, Rijken PF, Peters H, et al. The effect of the anti-angiogenic agent TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice. J Neurooncol. 1998; 38(1): 51-57
165. Devineni D, Klein Szanto A, Gallo JM. Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. Cancer Res. 1996, 56(9): 1983-1987
166. Joe YA, Hong YK, Chung DS, et al. Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3. Int J Cancer. 1999,82(5): 694-699
167. Kitsch M, Strasser J, Allende R, et al. Angiostatin suppresses malignant glioma growth in vivo. Cancer Res. 1998, 58(20): 4654-4659
168. Tanaka T, Cao Y, Folkrnan J, et al. Viral vectur-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res. 1998,58(15): 3362-3369
169. Griscelli F, Li H, Bennaceur Griscelli T, et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA. 1998, 95(11): 6367-6372
170. Wolff JE, Molenkamp G, Hotfilder M, et al. Dexamethasone inhibits glioma-induced formation of capillary like structures in vitro and angiogenesis in vivo. Klin Padiatr. 1997, 209(4): 275-7
171. Tanaka T, Manome Y, Wen P, et al. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med. 1997,3(4):437-42
172. Douglas R Malinowski J, Evan Sadler, et al. Characterization of a complementary deoxyribonucleic acid coding for human and bovine plasminogen. Biochemistry. 1984,23,4243-4250
173. Ponting, GP. Marshall, JM, Cederholm WS, et al. Plasminogen: a structural review. Blood Coagul & Fibrinolysis. 1992, (3): 605-614
174. Nick M, Louis CS, Robert FK, et al. Construction, expression and purification kringle 1 of human plasminogen and analysis of its interaction with ω-amino acids. Biochemistry. 1991,30, 1948-1957
175. Daniel M, Johann S, Brigitte O, et al. Expression, purification and characterization of the recombinant kringle 2 and kringle 3 domains of human plasminogen and analysis of their binding affinity for ω-aminocarboxylic acids. Eur J Biochem. 1994,219,455-462
176. Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science. 1970,170(4): 1095-1096
177．司徒镇强 吴军正 主编．细胞培养．西安：世界图书出版公司，1996．P147
178. Nelson NJ. lnhibitors of angiogenesis enter phase Ⅲ testing. J Natl Cancer Inst. 1998, 90(13):960-3
2. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267:10931-4.
3. Shalaby F.Failure of blood-island formation and vasculogenesis in fit-1-deficient mice.Nature.1995; 376:62-66
4. Breier G, Risau W. The role of VEGF in blood vessel formation. Trends Cell Biol.l996;6:454-456
5. Sato TN. Distinct roles of the receptor tyrosine kinases tie-1 and tie-2 in blood vessel formation.Nature.1995; 376:70-74
6. Henkemeyer M.Vascular system defects and neuronal apoptosis in mice lacking Ras GTPase activating protein.Nature.l984;307:648-649
7. Federico B, Alberto M, Graziella P, et al. Molecular mechanisms of blood vessel formation.Trends in Biochenmical Sciences. 1997;22(7):251 -256
8. Werner Risau. Mechanism of angiogenesis. Nature. 1997, 386:671-674
9. Dameron KM, Volpert OV, Tainsky MA,et al. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb Symp Quant Biol 1994; 59:483-9.
10. Rastinejad F, Polverini PJ, Bouck NP. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989; 56:345-55.
11. Plate KH, Breier G, Millauer B, et al. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat gliorna model of tumor angiogenesis. Cancer Res 1993; 53:58227.
12. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992; 359: 843-5
13. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145:574-84
14. Minchenko A, Bauer T, Salceda S, et al. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest. 1994; 71:374-9
15. Ensoli B, Gendelman R, Markham P, et al. Synergy between basic fibroblast growth factor and HIVA Tat protein in induction of Kaposi's sarcoma. Nature 1994; 371:674-80.
16. Nguyen JT, Wu P, Clouse MF, et al. Adcno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res.1998; 58:5673-7
17. Hannan RL, Kourembanas S, Flanders KC, et al. Endothelial cells synthesize basic fibroblast growth factor and transforming growth factor beta. Growth Factors. 1988; 1: 7-17
18. Mignatti P, Rifkin DB. Release of basic fibroblast growth factor, an angiogenic factor devoid of secretory signal sequence: a trivial phenomenon or a novel secretion mechanism? J Cell Biochem. 1991; 47:201-7
19. Klagsbrun M, D'Amore PA. Regulators of angiogenesis. Annu Rev Physiol. 1991; 53:217-39
20. Hori A, Sasada R, Matsutani E, et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res. 1991; 51:6180-4
21. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem. 1996; 271:603-6
22. Stokes CL, Rupnick MA, Williams SK, et al. Chemotaxis of human microvessel endothelial cells in response to acidic fibroblast growth factor. Lab Invest. 1990; 63:657-68
23. Guo D, Jia Q, Song HY, Warren Rs et al. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem. 1995; 270:6729-33
24. Relf M, LeJeune S, Scott PA et al. Expression of the angiogenic factors: vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997; 57:963-9
25. Gnarra JR, Duan DR, Weng Y et al. Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta. 1996; 1242:201-10
26. Yang EY, Moses HL. Transforming growth factor beta 1 -induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol. 1990; 111:731-41
27. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995; 146:1029-39
28. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Fit4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. Embo J. 1996; 15:290-98
29. Maglione D, Guerriero V, Viglietto G, et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A. 1991; 88:9267-71
30．寿成超．血管内皮细胞的增殖调节与抗血管肿瘤生物治疗．中国肿瘤生物治疗杂志．1999，6(3)：175～176
31. Bagavandoss P, Wilks JW. Specific inhibition of endothelial cell proliferation by thrombospondin. Biochern Biophys Res Commun. 1990; 170:867-7231
32. Rastinejad F, Polverini PJ, Bouck NP. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell; 1989; 56:345-55
33. Tolsma SS, Volpert OV, Good DJ et al. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol. 1993; 122:497-511
34．袁玫．靶向血管治疗肿瘤的研究进展．中国肿瘤生物治疗杂志．1999，6(3)：177～178
35. Sgadari C, Angiolillo AL, Cherney BW et al. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci U S A. 1996; 93:13791-6
36. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol. 1997; 61:246-57
37. Harmeken A, Ying W, Ling N, et al. Identification of soluble forms of the fibroblast growth factor receptor in blood. Proc Natl Acad Sci U S A.1994; 91:9170-4
38. Goldman CK, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A 1998; 95:8795-800
39. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994; 79:315-28
40. Dong Z, Yoneda J, Kumar R, et al. Angiostatin-mediated suppression of cancer metastases by primary, neoplasms engineered to produce granulocyte/macrophage colony stimulating factor. J Exp Med.1998; 188:755-63
41. Gately S, Twardowski P, Stack MS, et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci U S A. 1997; 94:10868-72
42. Cao Y, Ji RW, Davidson D, et al. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem. 1996; 271:29461-7
43. Cao Y, Chen A, An SSA, et al. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem. 1997; 272:22924-8
44. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma Cell 1994,79(2): 185-8
45. O'Reilly MS, Holmgren L, Chen C, et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996,2(6): 689-92
46. Dong Z, Kumar R, Yang X, et al. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997,88(6): 801-10
47. Gately S, Twardowski P, Stack MS, et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 1997,94(20): 10868-72
48. Sim BK, O'Reilly MS, Liang H, et al. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 1997,57(7): 1329-34
49. Marcia Barinaga. A Surprising Partner for Angiostatin. Cancer E A Surprising Partner for Angiostatin. Cancer Res.1999; 283(5409): 1831～3
50. O'Reilly MS, Holingren L, Chen C, Folkinan J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 1996; 2:689-92
51. Kim KJ, Li B, Winer J et al. inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362:841-4
52．吴景文，章翔．血管抑素与肿瘤的抗血管生成治疗．国外医学肿瘤学分册．1998；25(6)：16～17
53. Cao Y, O'Reilly MS, Marshall B, et al. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest. 1998, 101(5):1055-63
54. O'Reilly MS. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. EXS 1997;79:273-94
55. Oh SP, Kamagata Y, Muragaki Y et al. Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa, repeats identify a distinct family of collagenous proteins. Proc Nati Acad Sci U S A. 1994; 91:4229-33
56. Rehn M, Pihlajaniemi T. Identification of three N-terminal ends of type ⅩⅧ collagen chains and tissue specific differences in the expression of the corresponding transcripts. The longest form contains a novel motif homologous to rat and Drosophila frizzled proteins. J Biol Chem. 1995; 270:4705- 11
57. Muragaki Y, Timmons S, Griffith CM, et al. Mouse Coll. 8al is expressed in a tissuespecific manner as three alternative variants and is localized in basement membrane zones. Proc Natl Acad Sci U S A. 1995; 92:8763-7
58. Chen QR, Kumar D, Stass SA, et al. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 1999;59(14):3308-12
59. Cirri L, Donnini S, Morbidelli L, et al. Endostatin: a promising drug for antiangiogenic therapy. Int J Biol Markers 1999 Oct-Dec;14(4):263-7
60. Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997 ,390(6658):404-7
61. Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science. 1980; 208:516-8
62. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 1987; 47:5155-61
63. Voest EE, Kenyon BM, O'Reilly MS et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995; 87:581-6
64. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by interferon inducible protein. Blood. 1996; 87:3877-82
65. Yao L, Sgadari C, Furuke K et al. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood. 1999; 93:1612-21
66. Chen WT, Proteases associated with invadopodia with invadopodia, and their role in degradation of extracellular matrix. Enzyme Protein 1996; 49: 59-71
67. Johnson MD, Kim HR, Chesler L, Tsao-Wu G, Bouck N, Polverini PJ. Inhibition of angiogenesis by tissue inhibititor of metalloproteinase. J Cell Physiol 1994; 160: 194-202
68. Consalvo M, Mullen CA, Modesti A, et al. 5-Fluorocytosine-indueed eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 1995:154: 5302-12
69. Gastl G, Hermann T, Steurer M, et al. Angiogenesis as a target for tumor treatment. Oncology 1997; 54: 177-84
70. Wojtowicz-Praga S, Low J, Marshall J, et al. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in the patients with advanced cancer. Invest New Drugs. 1996; 14: 193-202
71. Folkman J, Iigber DE. Angiostatic steroids. Method of discovery and mechanism of action. Ann Surg 1987; 206: 374-83
72. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-63
73. Shokravi MT, Marcus DM, Alroy J, et al. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci. 1995;36:83-7
74. Ingber D, Fujita A, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature. 1990;348:555-7
75. Olson KA, Fett JW, French TC, et al. Angiogenin antagonists prevent tumor growth in vivo. Proc Natl Acad Sci USA. 1995;92: 442-6
76. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841-4.
77. Brook PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antigonists promote tumor regression by inducing apoptosis of angiogenic blood vessels.Cell.1994; 79:1157-64
78. Yeh CH, Peng HC, Huang TF. Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis. Blood, 1998; 92:3268-76
79. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:11826.
80. Panl MR. Starve the tumor, save the patient. The Lancet.1997, 349(11): 108-113
81. Folkman J. What is the evidence that tumors are angiogenesis dependent ? J Natl Cancer Inst. 1990,82(1):406
82. Folkman J, Watson K, Ingber D, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339:58-6 1
83. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324:1-8
84. Bouck N. Tumor angiogenesis: the role of oncogenes and tumor suppressor genes. Cancer cells. 1990; 2: 179-85
85. Dameron KM, Volpert OV, Tainsky MA, et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 1994; 265: 1582-4.
86. Folkman J, Waston K, Ingber D, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989; 339:58-61
87. Nanus DM, Schmitz-Drager BJ, Motzer RJ, et al. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst. 1993; 85:1597-9
88. Toim M, Hoshina S, Takayanagi A, et al. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary beast cancer. Jpn J Cancer Res. 1994; 85:1045-9
89. Takahashi Y, Kitadai Y, Bucana CD, et al. Expression of vascular endothlial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer. Cancer Res.1995; 55:3964-8
90. Yeicher BA, Holden SA, Ara G, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents, Int J Cancer. 1994; 57:920-5
91．董志伟．肿瘤控制与生物技术．中国肿瘤生物治疗杂志．1999，6 (3)：165
92. Burke F. Cytokines (IFNs, TNF-alpha, IL-2 and IL-12) and animal models of cancer. Cytokines Cell Mol Ther. 1999,5(1): 51-61
93. Nanni P, Forni G, Lollini PL. Cytokine gene therapy: hopes and pitfalls.Ann Oncol. 1999; 10(3): 261-6
94. Ockert D, Schmitz M, Hampl M, et al. Advances in cancer immunotherapy. Immunol Today. 1999; 20(2): 63-5
95. Prince HM. Gene transfer: a review of methods and applications. Pathology. 1998; 30(4): 335-47
96. Mueller H.Tumor necrosis factor as an antineoplastic agent: pitfalls and promises. Cell Mol Life Sci. 1998; 54(12): 1291-8
97. Kircheis R, Kupcu Z, Wallner G, et at. Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2+IFN-gamma. Cytokines Cell Mol Ther. 1998; 4(2): 95-103
98. Hwu P, Rosenberg SA.The genetic modification of T cells tbr cancer therapy: an overview of laboratory and clinical trials. Cancer Detect Prev. 1994; 18(1): 43-50
99. Pardoll DM. New strategies for enhancing the immunogenicity of tumors.Curr Opin Immunol. 1993; 5(5): 719-25
100. Kouraklis G. Progress in cancer gene therapy. Acta Oncol. 1999; 38(6): 675-83
101. Kuriyama S, Kikukawa M, Masui K, et al. Cancer gene therapy with HSV-tk/GCV system depends on Tcell-mediated immune responses and causes apoptotic death of tumor cells in vivo. Int J Cancer. 1999; 83(3): 374-80
102. Myers IN. The use of biological therapy in cancer of the head and neck. Curr Probl Cancer. 1999; 23(3): 106-34
103. Fueyo J, Gomez Manzano C, Yung WK, et al. Targeting in gene therapy for gliomas.Arch Neurol. 1999; 56(4): 445-8
104. Rainov NG, Ikeda K, Qureshi NH, et al. lntraarterial delivery, of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms. Hum Gene Ther. 1999; 10(2): 311-8
105. Sasaki M, Plate KH.Gene therapy of malignant glioma: recent advances in experimental and clinical studies. Ann Oncol. 1998; 9(11): 1155-66
106. Rosenberg SA. Immunotherapy and gene therapy of cancer. Cancer Res. 1991; 51 (18 Suppl): 5074s-5079s
107. Herrmann F. Cancer gene therapy: principles, problems, and perspectives. J Mol Med. 1995; 73(4): 157-63
108. Chen J, Gamou S, Takayanagi A, et al. Receptor-mediated gene delivery, using the Fab fragments of antiepidermal growth factor receptor antibodies: improved immunogene approach. Cancer Gene Ther. 1998; 5(6): 357-64
109. Fahraeus R, Fischer P, Krausz E, et al. New approaches to cancer therapies. J Pathol. 1999; 187(1): 138-46
110. Visse E, Siesjo P, Widegren B, et al. Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-gamma, interleukin-7, or B7-1-transfected tumor cells. Cancer Gene Yher. 1999; 6(1): 37-44
111. Horton HM, Anderson D, Hernandez P, et al. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc-Natl-Acad-Sci-U-S-A. 1999; 96(4): 1553-8
112. Wang JM, Deng X, Gong W, et al. Chemokines and their role in tumor growth and metastasis. J-Immunol-Methods. 1998; 220(1-2): 1-17
113. D'Angelica M, Fong Y. Cytokine gene therapy for human tumors.Surg Oncol Clin N Am. 1998; 7(3): 537-63
114. Chung RY, Chiocca EA. Gene therapy for tumors of the central nervous system.Surg Oncol Clin N Am. 1998; 7(3): 589-602
115. Mastrangelo MJ, Sato A, Lattime EC,et al. Cellular vaccine therapies for cancer. Cancer Treat Res. 1998; 94: 35-50
116. Weber CE. Cytokine-modified tumor vaccines: an antitumor strategy revisited in the age of molecular medicine. Cancer Nurs. 1998; 21(3): 167-77
117. Farzaneh F, Trefzer U, Sterry W, et al. Gene therapy of cancer. Immunol Today. 1998; 19(7): 294-6
118．崔正言．肿瘤疫苗的发展现状及其在肿瘤治疗中地位与前景．中国肿瘤生物治疗杂志．1999，6(3)：169
119. Kwak LW. Tumor vaccination strategies combined with autologous peripheral stem cell transplantation. Ann Oncol. 1998; 9 Suppl 1:S41-6
120. Gilboa E. Immunotherapy of cancer with genetically modified tumor vaccines. Semin Oncol. 1996; 23(1): 101-7
121. Hargest R, Williamson R. Expression of the APC gene after transfection into a colonic cancer cell line.Gut. 1995; 37(6): 826-9
122．钱振超．胂瘤疫苗的研究、直用与开发—21世纪的展望．中国肿痛生物治疗杂志．1999，6(3)：167—168
123．魏于全．肿瘤疫苗研究进展-利用异种细胞及异种基因进行肿瘤免疫治疗及基因治疗．中国肿瘤生物治疗杂志．1999，6(3)：176
124. Spear MA, Herrlinger U, Rainov N, et al. Targeting gene therapy vectors to CNS malignancies. J Neurovirol. 1998; 4(2): 133-47
125. Primus FJ, Finch MD, Wetzel SA, et al. Monoclonal antibody gene transfer: implications for tumor-specific cell-mediated cytotoxicity. Ann N Y Acad Sci. 1994; 716: 154o65; discussion 165-6
126. Mary, MN, Venot C, Caron de Fromentel C, et al. A tumor specific single chain antibody dependent on gene expression system. Oncogene. 1999; 18(2): 559-64
127．储大同．单克隆抗体的临床肿瘤应用进展．中国肿瘤生物治疗杂志．1999，6(3)：172
128. Spear MA. Gene therapy of gliomas: receptor and transcriptional targeting. Anticancer Res. 1998; 18(5A): 3223-31
129. Cirielli C, Capogrossi MC, Passaniti A. Anti-tumor gene therapy.J Neurooncol. 1997; 31 (1-2): 217-23
130. Hung MC, Matin A, Zhang Y, et al. HER-2/neu-targeting gene therapy-a review. Gene. 1995; 159(1): 65-71
131. Fathallah Shaykh H. New molecular strategies to cure brain tumors.Arch Neurol. 1999; 56(4): 449-53
132. Weyerbrock A, Oldfield EH. Gene transfer technologies for malignant gliomas. Curr Opin Oncol. 1999; 11(3): 168-73
133. Bellone M, Iezzi G, Imro MA, et al. Cancer immunotherapy: synthetic and natural peptides in the balance. Immunol Today. 1999, 20(10): 457-62
134. Braun SE, Chen K, Blazar BR, et al. Flt3 ligand antitumor activity in a murine breast cancer model: a comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action. Hum Gene Ther. 1999, 10(13): 2141-51
135. Avgeropoulos NG, Batchelor TT. New treatment strategies for malignant gliomas. Oncologist. 1999; 4(3): 209-24
136. Unger C. Current concepts of treatment in medical oncology: new anticancer drugs. J Cancer Res Clin Oncol. 1996; 122(4): 189-98
137. Mayer LD. Future developments in the selectivity of anticancer agents: drug delivery and molecular target strategies.Cancer Metastasis Rev. 1998; 17(2): 211-8
138. Ledley FD, Nonviral gene therapy: the promise of genes as pharmaceutical products. Hum Gene Ther. 1995; 6(9): 1129-44
139．丁锡申．基因重组药物的研究进展．中国肿瘤生物治疗杂志．1999．6(3)：173
140. Ronchetti A, Rovere P, Iezzi-G, et al. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J Immunol. 1999; 163(1): 130-6
141. McDonnell TJ, Meyn RE, Robertson LE. Implications of apoptotic cell death regulation in cancer therapy. Semin Cancer Biol. 1995; 6(1): 53-60
142．马大龙．细胞凋亡与肿瘤生物治疗．中国肿瘤生物治疗杂志．1999，6(3)：168
143. Cristiano RJ. Viral and non-viral vectors for cancer gene therapy. Anticancer Res. 1998; 18(5A): 3241-5
144. Cao Y.Therapeutic potentials of angiostatin in the treatment of cancer. Haematologica. 1999; 84(7): 643-50
145. Chen QR, Kumar D, Stass SA, et al. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res. 1999, 59(14): 3308-12
146. Malonne H, Langer I, Kiss R, et al. Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors. Clin-Exp-Metastasis. 1999; 17(1): 1-14
147. Blezinger P, Wang J, Gondo M, et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol. 1999; 17(4): 343-8
148. Liu Y, Thor A, Shtivelman E, et al. Systemic gene delivery expands the repertoire of effective antiangiogenic agents.J Biol Chem. 1999; 274(19): 13338-44
149. Lin P, Buxton JA, Acheson A, et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA. 1998; 95(15): 8829-34
150. Goldman CK, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc-Natl-Acad-Sci-U-S-A. 1998; 95(15): 8795-800
151. Paillard F. Suppression of angiogenesis: a means to fight cancer. Hum Gene Ther. 1998; 9(6): 768-70
152. Saleh M, Stacker SA, Wilks AF. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. 1996; 56(2): 393-401
153．寿超成．血管内皮细胞的增殖调节与抗血管肿瘤生物治疗．中国肿瘤生物治疗杂志．1999，6(3)：175-176
154．袁玫．靶向血管治疗肿瘤的研究进展．中国肿瘤生物治疗杂志．1999，6(3)：177
155. Ohnishi T, Sher PB, Posner HB et al. Capillary permeability factor secreted by malignant brain tumor: role in peritumoral grain edema and possible mechanism for antiedema effect of glucorticoids. J Neurosurgery,1990; 72:245-251
156. Folkman J, Shing Y. Angiogenesis. J Biol Chem, 1992; 267:10931-10934
157. KJ Kim, B Li, J Winer, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppress tumor growth in vivo. Nature, 1993;362:841-844
158. Saleh M, Stacker SA, Wilks A. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res,1996;56:393-401
159. Im SA, Gomez-Manzano C, Fueyo J, et al. Antiangiogenesis treatment for gliomas: transfer of antisensevascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res. 1999; 15; 59(4):895-900.
160. Weindel K, Moringlane JR, Marine D. Detection and quantification of vascular endothelial growth factor in brain tumor tissue and cyst fluid: the key to angiogenesis. Neurosurgery, 1994;35:439-449
161. Takano S. Suramin inhibits glioma cell proliferation in vitro and in the brain. J Neuro Oncol, 1994; 21:189-201
162. Fan TP. Angiosuppressive therapy for cancer. TIPS, 1994;1533-1535
163. Taki T, Ohnishi T, Arita N, et al. Anti-proliferative effects of TNP-470 on human malignant glioma in vivo: potent inhibition of tumor angiogenesis. J Neurooncol. 1994, 19(3): 251-258
164. Bernsen HJ, Rijken PF, Peters H, et al. The effect of the anti-angiogenic agent TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice. J Neurooncol. 1998; 38(1): 51-57
165. Devineni D, Klein Szanto A, Gallo JM. Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. Cancer Res. 1996, 56(9): 1983-1987
166. Joe YA, Hong YK, Chung DS, et al. Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3. Int J Cancer. 1999,82(5): 694-699
167. Kitsch M, Strasser J, Allende R, et al. Angiostatin suppresses malignant glioma growth in vivo. Cancer Res. 1998, 58(20): 4654-4659
168. Tanaka T, Cao Y, Folkrnan J, et al. Viral vectur-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res. 1998,58(15): 3362-3369
169. Griscelli F, Li H, Bennaceur Griscelli T, et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA. 1998, 95(11): 6367-6372
170. Wolff JE, Molenkamp G, Hotfilder M, et al. Dexamethasone inhibits glioma-induced formation of capillary like structures in vitro and angiogenesis in vivo. Klin Padiatr. 1997, 209(4): 275-7
171. Tanaka T, Manome Y, Wen P, et al. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med. 1997,3(4):437-42
172. Douglas R Malinowski J, Evan Sadler, et al. Characterization of a complementary deoxyribonucleic acid coding for human and bovine plasminogen. Biochemistry. 1984,23,4243-4250
173. Ponting, GP. Marshall, JM, Cederholm WS, et al. Plasminogen: a structural review. Blood Coagul & Fibrinolysis. 1992, (3): 605-614
174. Nick M, Louis CS, Robert FK, et al. Construction, expression and purification kringle 1 of human plasminogen and analysis of its interaction with ω-amino acids. Biochemistry. 1991,30, 1948-1957
175. Daniel M, Johann S, Brigitte O, et al. Expression, purification and characterization of the recombinant kringle 2 and kringle 3 domains of human plasminogen and analysis of their binding affinity for ω-aminocarboxylic acids. Eur J Biochem. 1994,219,455-462
176. Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science. 1970,170(4): 1095-1096
177．司徒镇强 吴军正 主编．细胞培养．西安：世界图书出版公司，1996．P147
178. Nelson NJ. lnhibitors of angiogenesis enter phase Ⅲ testing. J Natl Cancer Inst. 1998, 90(13):960-3